Adverse events as N of participants with at least one adverse event objective · people with drug‐resistant focal epilepsy
Brivaracetam showed no clear difference in proportion of participants who experienced any adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Grade 3 to 4 neutropenia · non‐small cell lung cancer in the elderly population
Non‐platinum single‐agent may leads to higher grade 3 and 4 hematological adverse events (AE) ‐ neutropenia compared with non‐platinum combination treatment (low certainty).
1 finding from 1 review
Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma
It is very uncertain whether adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver… changes adverse events considered non‐serious (number of participants) compared with liver transplantation (very low certainty).
1 finding from 1 review
Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma
It is very uncertain whether E1B‐deleted (dl1520) adenovirus changes adverse events considered non‐serious (number of participants) compared with percutaneous ethanol injection (very low certainty).
1 finding from 1 review
Adverse events considered non‐serious · participants with advanced hepatocellular carcinoma
It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes adverse events considered non‐serious (number of participants) compared with best supportive care alone (very low certainty).
1 finding from 1 review
Proportion of participants experiencing adverse events · people with focal epilepsy
Losigamone showed no clear difference in the proportion of participants experiencing any adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events (reported at any time) (2 RCT, 169 participants) · adults with blepharospasm
Botulinum toxin type A showed no clear difference in adverse events (reported at any time) (2 RCT, 169 participants) compared with placebo (low certainty).
1 finding from 1 review
RR 1.18 [0.87, 1.6]
Studies not reported
Low
Intervention not reported
Adverse events: a. mild hypoglycaemia (episodes per participant)
1 finding from 1 review
Intervention not reported
Adverse events: a. mild hypoglycaemia (episodes per participant)
1 finding from 1 review
Number experiencing adverse effects · children (12 or over) and adults with cystic fibrosis and lung infection
It is very uncertain whether summary of findings: monoclonal antibody KB001‐A changes adverse events number of participants experiencing adverse events compared with placebo (very low certainty).
1 finding from 1 review
Discontinued treatment due to adverse events measured at a median · men with metastatic, hormone‐sensitive prostate cancer
Abiraterone + ADT probably leads to higher discontinued treatment due to adverse events measured at a median compared with ADT alone (moderate certainty).
1 finding from 1 review
Specific adverse events: gastrointestinal perforations or fistulae · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether pazopanib plus lapatinib changes specific adverse events: gastrointestinal perforations or fistulae compared with lapatinib (very low certainty).
1 finding from 1 review
Specific adverse events: gastrointestinal perforations or fistulae · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether pazopanib changes specific adverse events: gastrointestinal perforations or fistulae compared with lapatinib (very low certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events: serum glutamic‐ pyruvic transaminase (SGPT) · antiretroviral‐naïve individuals
1 finding from 1 review
Safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4 according to National Cancer Institute · non‐small cell lung cancer in the elderly population
It is very uncertain whether non‐platinum single‐agent changes grade 3 and 4 hematological adverse events (AE) ‐ thrombocytopenia compared with non‐platinum combination treatment (very low certainty).
1 finding from 1 review
Proportion of people with ≥ 1 serious adverse events (at 20 months) · participants with advanced hepatocellular carcinoma
It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes proportion of people with ≥ 1 serious adverse events (at 20 months) compared with best supportive care alone (very low certainty).
1 finding from 1 review
Adverse events number of participants hospitalised during the trial · children with cystic fibrosis
Summary of findings: Zinc supplementation showed no clear difference in adverse events number of participants hospitalised during the trial compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events Any untoward medical occurrence regarding medications · people with neurosyphilis
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Very low
Proportion of people with ≥ 1 serious adverse events during treatment · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of people with ≥ 1 serious adverse events during treatment · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found